FutureBridge invites you to their event

Gene Editing-Beyond CRISPR

About this event

Gene editing techniques have witnessed significant traction since CRISPR / CaS9 was discovered. The editing technology has complexities and challenges like the need for palindromic sequence before & after the gene of interest, purification, and expression of CaS nuclease, delivery of gRNA, acting in a non-specific manner resulting in off-shoot mutations and cell toxicity. Despite these limitations, there was a multi-fold interest in the research community to capitalize CRISPR/ CaS9 tool in editing targeted gene sequences.

In recent times, technologies such as TALEN, ZFN, NgAgO, Lambda Red had emerged as novel gene-editing tools having wider applicability with sequence specificity.

Join our webinar to learn:

  • What are the limitations of CRISPR/CaS9 as a gene-editing tool and approaches to overcome these?
  • What is the penetration level of new gene-editing tools across therapy areas?
  • How will this penetration evolve in the next few years across different therapy areas?
  • What is the evolving landscape of - innovations, key players and start-ups, and partnerships?

Hosted by

  • Team member
    T
    Inayat H. Sheikh, PhD Senior Consultant @ FutureBridge

    I am responsible for FutureBridge Pharma & Biotech vertical which provides comprehensive analysis and research for innovation roadmap, assessing drug pipeline and unmet needs enroute to market

FutureBridge

Be the Future.

FutureBridge is a techno-commercial consulting and advisory company.

We track and advise on the future of industries from a 1-to-25-year perspective to keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and fac